Prognostic value of circulating clonal plasma cells in newly diagnosed multiple myeloma. Issue 1 (1st January 2021)

• Record Type: Journal Article
• Authors: Han, Wenmin; Jin, Yuanyuan; Xu, Min; Zhao, Si-Shu; Shi, Qinglin; Qu, Xiaoyan; Zhang, Run; Li, Jianyong; Wu, Yujie; Chen, Lijuan
• Is Part Of: Hematology. Volume 26:Issue 1(2021)
• Page Start: 510
• Page End: 517
• Publication Date: 2021-01-01
• Subjects: Circulating plasma cells -- multiple myeloma -- prognosis -- risk stratification -- high-risk patients -- R-ISS staging system -- flow cytometry -- minimal residual disease; Blood -- Diseases -- Periodicals; Hematology -- Periodicals; Blood -- Transfusion -- Periodicals; 616.15005
• DOI: 10.1080/16078454.2021.1948208
• Languages: English
• ISSNs: 1024-5332

Abstract

ABSTRACT: Objectives: Multiple myeloma (MM) involves a clinically and biologically heterogeneous malignancy of plasma cells. It is difficult to predict the prognosis of MM. The presence of circulating clonal plasma cells (CPC) has been associated with a worse prognosis in patients with MM. Methods: This study retrospectively analysed CPC in 108 newly diagnosed MM patients by 8-colour flow cytometry to investigate their value for predicting the outcome and combined the level of CPC with the revised International Staging System (R-ISS) to stratify the MM patients according to risk. Results: CPC were detected in 58/108 patients (53.7%). The optimum cut-off for the prediction of overall survival was determined to be 0.105%. Patients with higher R-ISS stages seemed to harbour more CPC. A level of CPC≥0.105% was an independent risk factor for adverse outcomes ( P <0.001). The combination of the R-ISS staging system and level of CPC was used to stratify MM patients according to risk, and the combination of R-ISS stage III and a level of CPC≥0.105% defined the ultra-high-risk group. Conclusion: This study suggests that a high proportion of CPC is associated with aggressive disease and that the use of the current R-ISS system in conjunction with assessment of the level of CPC may facilitate the stratification of newly diagnosed MM patients into clinically relevant prognostic subgroups.